Doximity, Inc.
HealthcareNYSE:DOCS · New York Stock Exchange
+$0.02 today
Vol 1.98M · Avg 3.86M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$644.9M of revenue converted into $196.1M of net income for the selected period. Gross margin is 89.0% and net margin is 29.9%, showing how much revenue survives after costs and taxes. EPS is $0.99, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $644.9M +13.1% | $570.4M +20.0% | $475.4M +13.5% | $419.1M +22.0% | $343.5M | $1.0B | $809.6M | $921.6M |
| Cost of Revenue | $70.3M +25.9% | $55.9M +10.3% | $50.7M -5.3% | $53.5M +34.4% | $39.8M | $344.8M | $725.6M | $804.0M |
| Gross Profit | $574.5M +11.7% | $514.5M +21.1% | $424.8M +16.2% | $365.6M +20.3% | $303.8M | $10.3B | $8.9B | $7.6B |
| Gross Margin | 89.1% -1.1pp | 90.2% +0.9pp | 89.3% +2.1pp | 87.2% -1.2pp | 88.4% | 45.5% | 9.8% | 28.9% |
| Research & Development | $130.7M +40.5% | $93.0M +13.5% | $82.0M +2.2% | $80.2M +28.6% | $62.4M | $378.4M | $983.2M | $1.3B |
| Selling, General & Admin | $228.9M +19.6% | $191.4M +11.9% | $171.0M +6.7% | $160.3M +25.3% | $127.9M | $1.4B | $620.6M | $923.0M |
| Operating Expenses | $359.6M +25.4% | $286.7M +9.9% | $260.9M +8.5% | $240.5M +26.4% | $190.2M | $3.6B | $5.3B | $7.0B |
| Depreciation & Amortization | $0 -100.0% | $10.7M +3.8% | $10.3M -0.2% | $10.3M +104.0% | $5.0M | $1.2B | $374.2M | $1.2B |
| EBITDA | $250.0M +3.8% | $240.8M +32.2% | $182.1M +26.9% | $143.4M +20.5% | $119.0M | $12.6B | -$15.2B | $6.8B |
| EBITDA Margin | 38.8% -3.4pp | 42.2% +3.9pp | 38.3% +4.1pp | 34.2% -0.4pp | 34.7% | 10.0% | 5.6% | 46.3% |
| Operating Income | $214.9M -5.7% | $227.8M +39.0% | $163.9M +31.0% | $125.1M +10.2% | $113.5M | $10.6B | $12.3B | $14.0B |
| Operating Margin | 33.3% -6.6pp | 39.9% +5.5pp | 34.5% +4.6pp | 29.9% -3.2pp | 33.0% | 18.7% | 16.6% | 24.1% |
| Interest Income | $0 -100.0% | $35.9M +65.5% | $21.7M +133.3% | $9.3M +332.4% | $2.1M | $1.3B | -$1.5B | -$1.6B |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $969.2M | $1.1B | $1.0B |
| Other Income / Expenses | $35.1M -1.9% | $35.8M +67.8% | $21.3M +165.0% | $8.0M +1616.0% | $469.0K | -$1.6B | -$1.5B | $1.4B |
| Income Before Tax | $250.0M -5.1% | $263.6M +42.3% | $185.2M +39.1% | $133.2M +16.8% | $114.0M | -$15.6B | $3.3B | $4.9B |
| Pre-Tax Margin | 38.8% -7.4pp | 46.2% +7.3pp | 39.0% +7.2pp | 31.8% -1.4pp | 33.2% | 13.3% | 20.8% | 18.7% |
| Income Tax Expense | $54.0M +33.6% | $40.4M +7.4% | $37.6M +85.0% | $20.3M +149.9% | -$40.8M | $666.8M | $1.3B | -$1.6B |
| Net Income | $196.1M -12.2% | $223.2M +51.2% | $147.6M +30.8% | $112.8M -27.1% | $154.8M | $5.0B | $4.9B | $4.8B |
| Net Margin | 30.4% -8.7pp | 39.1% +8.1pp | 31.0% +4.1pp | 26.9% -18.1pp | 45.1% | 7.4% | 12.4% | 17.5% |
| EPS (Basic) | $1 -11.8% | $1 +52.6% | $1 +34.5% | $1 -28.4% | $1 | $1.2B | $400.8M | $703.2M |
| EPS (Diluted) | $1 -11.7% | $1 +54.2% | $1 +35.8% | $1 -24.3% | $1 | $620.6M | $766.2M | $609.4M |
| Weighted Avg Shares | $187.0M +0.1% | $186.8M -1.8% | $190.2M -1.6% | $193.2M +18.2% | $163.5M | $892.2M | $757.8M | $925.8M |
| Weighted Avg Shares (Diluted) | $199.0M -1.1% | $201.2M -2.2% | $205.7M -3.6% | $213.4M +11.7% | $191.0M | $319.6M | $1.2B | $924.4M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Exact Sciences Corporation
EXAS
$20.03B
Viatris Inc.
NASDAQ:VTRS
$19.19B
Guardant Health, Inc.
NASDAQ:GH
$17.45B
Solventum Corporation
NYSE:SOLV
$13.66B
The Cooper Companies, Inc.
NASDAQ:COO
$13.24B
ICON Public Limited Company
NASDAQ:ICLR
$11.19B
Revvity, Inc.
NYSE:RVTY
$11.12B
Encompass Health Corporation
NYSE:EHC
$10.07B
Tempus AI, Inc.
NASDAQ:TEM
$8.35B
HealthEquity, Inc.
NASDAQ:HQY
$7.39B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does DOCS generate?
Doximity, Inc. (DOCS) reported $644.86M of revenue in fiscal 2026.
Is DOCS profitable?
Doximity, Inc. (DOCS) reported $196.05M of net income, with a net margin of 30.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.